FDA Approval Application for Deflazacort Submitted by Carnegie
Carnegie has submitted an original application (ANDA220709) for Deflazacort, currently under standard review by the FDA.
Therapeutic Area
Therapeutic area intelligence for Autoimmune with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.